Cost-Effectiveness of Antiplatelet Agents in Secondary Stroke Prevention: The Limits of Certainty
Open Access
- 1 September 2005
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 8 (5), 572-580
- https://doi.org/10.1111/j.1524-4733.2005.00050.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysisAmerican Journal Of Medicine, 2004
- Aspirin Therapy Should Be First-Line Treatment in Secondary Prevention of Stroke—AgainstStroke, 2002
- Aspirin therapy should be first line: probably, but watch this space.Stroke, 2002
- Have Randomized Controlled Trials of Neuroprotective Drugs Been Underpowered?Stroke, 2001
- Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysisClinical Therapeutics, 2000
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokeJournal of the Neurological Sciences, 1996
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Probability of stroke: a risk profile from the Framingham Study.Stroke, 1991
- The Toss-upNew England Journal of Medicine, 1981